Introduction
============

Punctate inner choroidopathy (PIC) is an inflammatory chorioretinal disease of unknown etiology, first described by Watzke et al in 1984.[@b1-opth-4-871] It presents mostly in healthy, young, moderately myopic women[@b2-opth-4-871] with metamorphopsia and decreased visual acuity. On fundoscopy, small, creamy, yellow-white lesions, measuring 100--300 μm, located in the retinal pigment epithelium and inner choroid without concomitant intraocular inflammation are the hallmark of the early disease.[@b2-opth-4-871] The optic nerve head can be mildly swollen.[@b3-opth-4-871] Fluorescein angiography (FA) reveals areas with early hyperfluorescence and late leakage,[@b3-opth-4-871] whereas, remarkably, on indocyanine green angiography, more hypofluorescent spots than observed clinically or on FA are evident, with normal large choroidal vessels running through the hypofluorescent areas.[@b3-opth-4-871],[@b4-opth-4-871] At least 25%--40% of patients develop choroidal neovascularization (CNV), usually within the first 6 months, although CNV may occur years after the initial lesions. For the remaining 60%--75%, the visual prognosis is rather favorable with the majority of eyes retaining vision of 20/30 or better.[@b2-opth-4-871],[@b4-opth-4-871],[@b5-opth-4-871]

The variety of treatment options for the CNV in PIC reflects the puzzling absence of consistent results and includes submacular surgery,[@b6-opth-4-871],[@b7-opth-4-871] steroids,[@b4-opth-4-871],[@b8-opth-4-871],[@b9-opth-4-871] photodynamic therapy (PDT),[@b10-opth-4-871]--[@b16-opth-4-871] and most recently anti-VEGF agents.[@b17-opth-4-871],[@b18-opth-4-871] In cases of extrafoveal or juxtafoveal lesion, CNV laser photocoagulation can also be attempted.[@b4-opth-4-871] We report on the long-term outcome of a cohort of young adults with PIC complicated with CNV who either underwent PDT or left to follow the natural course of the disease.

Patients and methods
====================

The charts of patients with a definite diagnosis of PIC from September 1993 were identified and reviewed. A total of 9 eyes of 8 patients with actively leaking CNV were included in the study and retrospectively followed for a total of 36--162 months (average, 105 months). In 1 patient, there was bilateral involvement, whereas in 7 patients, the CNV was unilateral. Four eyes were treated with PDT, and 5 eyes were left untreated. The latter was considered an established treatment modality for CNV, before the introduction of PDT. The patient who suffered bilateral involvement was also administered interferon-2b (IFN-2b; 3 MU subcutaneously 3 times per week) for viral hepatitis-B diagnosed during the initial workup, and 1 patient had been treated with thermal laser prior to PDT ([Table 1](#t1-opth-4-871){ref-type="table"}).

Treatment with PDT followed the standard protocol and consisted of an intravenous infusion of 6 mg/m^2^ verteporfin (Visudyne^®^; Novartis AG, Bülach, Switzerland) for 10 minutes. Fifteen minutes after the initiation of the infusion, the photosensitizer was activated using a laser light of 689 nm delivered at 50 J/cm^2^ with an intensity of 600 mW/cm^2^ for 83 seconds. The treatment spot was set to cover the greatest linear dimension of the CNV lesion, with an additional 500 μm covering the borders on each side. FA was performed prior to PDT to evaluate the extent of CNV and repeated during follow-up to evaluate the CNV activity. Retreatment was considered in cases of residual leakage or reactivation.

Studied parameters included Snellen visual acuity and the extent of active neovascularization and subretinal fibrosis, as evaluated by reviewing the FA on presentation and at the end of follow-up period. Patient demographics, treatment, and final results are summarized in [Table 1](#t1-opth-4-871){ref-type="table"}.

Results
=======

Report of selected cases
------------------------

### Patient 1

A 36-year-old female myopic patient was initially referred in June 2001 with a right-sided visual impairment of 6-weeks duration. On presentation, best-corrected visual acuity (BCVA) amounted to 20/400 OD (ocular dexter) and 20/20 OS (ocular sinister) with a corresponding refractive error of −4.0D and −2.5D. Fundus examination revealed several scattered chorioretinal scars on the posterior pole of the affected eye and an extensive submacular exudative lesion, which angiographically corresponded to CNV ([Figure 1A](#f1-opth-4-871){ref-type="fig"}). PIC complicated with subfoveal CNV was diagnosed. The patient underwent standard PDT with a 4,200-μm spot size on July 2001, repeated once on February 2002. Three months following the second PDT session, BCVA had improved to 20/100 OD. Visual acuity remained stable during the follow-up period, whereas on FA a central chorioretinal scar without signs of leakage was evident ([Figure 1B](#f1-opth-4-871){ref-type="fig"}).

### Patient 2

A 21-year-old female myopic patient was initially referred in June 2004 with a 2-month history of floaters and decrease of vision from the left eye. Her refractive error was OD −4.5 D and OS −3.75 to 0.75 × 20, and on presentation, BCVA was 20/20 and 20/400, respectively. A typical picture of left-sided PIC complicated with CNV was evident on fundoscopy and FA. Upon diagnosis, the patient was treated with PDT with a 4,100-μm spot size. One month later, visual acuity had improved to 20/100 OS, but due to persistence of fluorescein leakage, the patient was retreated with PDT. In December 2004, visual acuity had improved to 20/30 OS, whereas the CNV remained angiographically inactive. At the end of a 3-year follow-up period, the visual acuity amounted to 20/25 OS without leakage on FA.

### Patient 3

A 35-year-old female myopic patient was referred in October 1996 with decreased vision and metamorphopsia in her left eye of 3 weeks duration. Myopic error was OD −4.0 D and OS −3.0 to 0.5 × 180 with a BCVA of 20/40 and 20/400, respectively. She reported an episode of central serous chorioretinopathy in her right eye 9 years earlier. Based on fundoscopy and FA findings, PIC complicated with subfoveal CNV was diagnosed. None of the treatment options was deemed effective at that time, and the disease was left to follow its natural course. Three months later, her visual acuity improved to 20/80 OS but subsequently deteriorated to less than 20/400 in July 1997. On FA, a large neovascular membrane was evident, which eventually progressed to an extensive disciform chorioretinal scar.

### Patient 5

A 22-year-old female myopic patient was initially referred in September 1993 with left eye visual impairment and metamorphopsia. Refractive error was OD −2.0 D and OS −2.5 D with a corresponding BCVA of 20/25 OD and 20/40 OS on Snellen optotype. A left eye subfoveal CNV was evident on FA. On general workup, active hepatitis B was diagnosed, and α-IFN-2b (3MU subcutaneously 3 times per week) was administered immediately until February 1994. Three months after her referral, although she was on the IFN treatment, she developed CNV in the right eye along with several discrete chorioretinal small scars with diameter of approximately 200--300 μm mainly around the optic disc. On February 1996, her visual acuity was 20/50 in the right eye and 20/100 in the left eye, which was stable in all consecutive follow-up examinations. Subsequent FAs confirmed the presence of chrorioretinal scars without leakage bilaterally.

### Patient 6

A 24-year-old female myopic patient (\[OD −3.0 to 0.75 × 115\] and \[OS −4.0 D\]) was initially referred in December 1995 with right eye visual impairment and metamorphopsia. BCVA on presentation was 20/70 OD and 20/25 OS. Fundus examination revealed a small exudative lesion that was leaking on FA in the right eye ([Figure 2A](#f2-opth-4-871){ref-type="fig"}) and several creamy, yellow-white lesions in the left eye with faint staining in the late phases of FA. None of the current treatment options was deemed effective, and the disease was left to follow its natural course. Three years later, an increase of the size of CNV was noted on FA, although visual acuity had improved to 20/30 OD. In subsequent follow-ups, visual acuity remained stable. On her last visit 11 years after the diagnosis of PIC, visual acuity was 20/30 in the right eye and 20/25 in the left eye, the FA showed juxtafoveal lesions with staining but without leakage in the right eye ([Figure 2A](#f2-opth-4-871){ref-type="fig"}) and some scattered chorioretinal slightly pigmented small lesion in the left eye.

Nine eyes of 8 female patients were retrospectively followed for an average of 105 months (range, 36--162 months) after the diagnosis of PIC associated with active CNV. Mean age of the patient group was 28 years (range, 21--39). Four eyes were initially treated with PDT, in 3 of which the treatment was repeated once due to active leakage on subsequent FA. The remaining 5 eyes were followed without treatment mainly due to the lack of a widely accepted effective treatment at the time of presentation.

Visual acuity on presentation measured 20/40 or better in 2 eyes (22.2%), ranged from 20/40 to 20/200 in 4 eyes (44.4%), and was 20/200 or worse in 3 eyes (33.3%). Improvement of vision was noted in 6 eyes at the end of the follow-up period (66.7%), including all cases treated with PDT, and in 2 of 5 eyes left untreated, and visual acuity deterioration was noted in 3 eyes (33.3%).

The size of the neovascular lesion, including both CNV and subretinal fibrosis, increased in 5 eyes (55.6%) and was stable in 4 eyes (44.4%) all treated with PDT. A trend toward better final visual acuity and stability of CNV activity was identified in the subgroup receiving PDT.

Discussion
==========

The management of CNV due to PIC has not been conclusively determined, as most published cohorts ([Table 2](#t2-opth-4-871){ref-type="table"}) report on small number of patients with short follow-up, including some with intermixed subfoveal and juxtafoveal CNV lesions. A variety of treatment options have been described, including PDT,[@b10-opth-4-871]--[@b16-opth-4-871] use of local and systemic steroid monotherapy,[@b2-opth-4-871],[@b4-opth-4-871],[@b9-opth-4-871] submacular surgery,[@b6-opth-4-871],[@b7-opth-4-871] and recently anti-VEGF agents.[@b17-opth-4-871],[@b18-opth-4-871] Corticosteroids have also been advocated as a therapeutic adjunct to PDT, in particular due to their dual anti-inflammatory and antiangiogenetic properties.[@b19-opth-4-871],[@b20-opth-4-871]

Oral steroids and laser photocoagulation were tried as early as 1984 by Watzke et al[@b1-opth-4-871] in their initial presentation of 10 cases of a clinical entity that they termed "PIC". Brown et al[@b2-opth-4-871] presented 5 patients who underwent oral and subtenon corticosteroid treatments, which reportedly slowed or stopped the subfoveal neovascularization, though without effect on final visual acuity which was less than 20/200 in all eyes. Submacular surgery was considered as a potential treatment of CNV due to PIC in 1995 by Adelberg et al,[@b7-opth-4-871] who reported 1 case with more than 2 lines of Snellen acuity gain at the end of the follow-up period. Olsen et al[@b6-opth-4-871] in 1996 reported further promising results in 5 patients (6 eyes) who underwent submacular surgery and noted visual improvement in all 6 eyes, although recurrences were common (4 out of 6 eyes). Sickenberg et al[@b11-opth-4-871] in 2000 presented 1 case treated with PDT and followed for 35 weeks with no change in visual acuity (20/100), whereas Rogers et al[@b10-opth-4-871] reported on 6 cases of PIC complicated with CNV and treated with PDT, and noted visual improvement in 4 eyes, decline in 1 and, stabilization in 1. Further reports on small cohorts of patients with PIC by Wachtlin et al,[@b12-opth-4-871] Chatterjee and Gibson,[@b13-opth-4-871] Postelmans et al,[@b14-opth-4-871] Lim et al,[@b15-opth-4-871] and Coco et al[@b16-opth-4-871] substantiate a general trend toward favorable results with PDT. Fong et al[@b21-opth-4-871] and Chan et al[@b22-opth-4-871] reported encouraging results on combined PDT with oral or intravitreal steroid. Finally, Vossmerbaeumer et al[@b17-opth-4-871] reported the successful outcome in a case of CNV secondary to PIC with intravitreal anti-VEGF treatment (bevacizumab), and Leung et al[@b18-opth-4-871] reported favorable results in a case with intravitreal ranibizumab after a short-term follow-up.

PDT is generally safe and effective for subfoveal CNV in age-related macular degeneration and high myopia. For other CNV etiologies, PDT is an option if outcome without treatment is likely to be poor, and preliminary success in ocular histoplasmosis syndrome, angioid streaks, idiopathic, and other conditions has been reported.[@b10-opth-4-871],[@b11-opth-4-871] Our results correlate with the ones reported by other authors[@b11-opth-4-871]--[@b16-opth-4-871] further substantiating PDT as an effective treatment option in CNV due to PIC. It also adds to relevant literature a small but significant cohort of patients with long-term follow-up, which highlights the prolonged effectiveness of PDT in this patient group. The natural course of the disease is also demonstrated in our study with the presentation of a number of patients left untreated. Some of this group retained a functional visual acuity even after a long follow-up, implying that active neovascularization may recede leaving macula relatively unharmed.

Allowing for obvious limitations, such as the small number of cases and the retrospective review of patient records, our study contributes mainly with the long-term follow-up to the limited body of literature regarding CNV due to PIC.
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![Case 1. Choroidal neovascularization with photodynamic therapy treatment. **A**) On presentation. **B**) At the end of 72-month follow-up period. The choroidal neovascularization is stable.](opth-4-871f1){#f1-opth-4-871}

![Case 6. Choroidal neovascularization without photodynamic therapy treatment. **A**) On presentation. **B**) At the end of 134-month follow-up period. There is an apparent increase of choroidal neovascularization.](opth-4-871f2){#f2-opth-4-871}

###### 

Patient demographics, refraction, and clinical course

  **Patient no.**   **Age at presentation**   **Gender**   **Eye**   **Refraction**       **Initial VA[a](#tfn1-opth-4-871){ref-type="table-fn"}**   **Treatment (sessions)**   **Follow-up (months)**   **Final VA[a](#tfn1-opth-4-871){ref-type="table-fn"}**   **CNV-subretinal fibrosis extent[b](#tfn2-opth-4-871){ref-type="table-fn"}**
  ----------------- ------------------------- ------------ --------- -------------------- ---------------------------------------------------------- -------------------------- ------------------------ -------------------------------------------------------- ------------------------------------------------------------------------------
  1                 36                        F            OD        −4.0                 20/400                                                     PDT (2)                    72                       20/100                                                   Stable
  2                 21                        F            OS        −3.75 to 0.75 × 20   20/400                                                     PDT (2)                    36                       20/25                                                    Stable
  3                 35                        F            OS        −3.0 to 0.5 × 180    20/400                                                     None                       124                      20/800                                                   Increased
  4                 29                        F            OS        −2.5                 20/80                                                      None                       126                      20/40                                                    Increased
  5                 22                        F            OD        −2.0                 20/25                                                      None                       159                      20/50                                                    Increased
  --                --                        --           OS        −3.0                 20/40                                                      None                       162                      20/100                                                   Increased
  6                 24                        F            OD        −3.0 to 0.75 × 115   20/70                                                      None                       134                      20/30                                                    Increased
  7                 39                        F            OS        −1.75 to 0.75 × 90   20/50                                                      PDT (1)                    48                       20/30                                                    Stable
  8                 21                        F            OD        −3.0 to 0.75 × 60    20/70                                                      Thermal laser or PDT (2)   84                       20/25                                                    Stable
  Average           28                        --           --        --                   --                                                         --                         105.0                    --                                                       --

**Notes:**

Snellen.

Compared with lesion extent on presentation.

**Abbreviations:** VA, visual acuity; CNV, choroidal neovascularization; OD, oculus dexter; OS, oculus sinister; PDT, photodynamic therapy.

###### 

Summary of existing literature

  **Year of publication**   **Author**                               **No. eyes**                                   **Follow-up**   **Treatment**                         **Comment**
  ------------------------- ---------------------------------------- ---------------------------------------------- --------------- ------------------------------------- ---------------------------------------------------------------------------
  1984                      Watzke et al[@b1-opth-4-871]             3                                              1, 5--8 y       No treatment or oral steroids         Decline in VA to 20/60 in 1 eye and 20/200 in 2 eyes
  1995                      Adelberg et al[@b7-opth-4-871]           1                                              13.5 mo         Submacular surgery                    From 20/300 to 20/70
  1996                      Brown et al[@b2-opth-4-871]              5                                              6 mo            No treatment or oral steroids         Final VA ≤20/200 in all eyes
  1996                      Olsen et al[@b6-opth-4-871]              6                                              14 mo           Submacular surgery                    VA improved in all eyes, 66% recurrence
  2000                      Sickenberg et al[@b11-opth-4-871]        1                                              35 wk           PDT                                   No change in VA (20/100)
  2003                      Rogers et al[@b10-opth-4-871]            6[a](#tfn4-opth-4-871){ref-type="table-fn"}    4--33 mo        PDT or retreatment in 4 cases         VA improvement in 4, deterioration in 1, and 1 with no change
  2003                      Wachtlin et al[@b12-opth-4-871]          7[b](#tfn5-opth-4-871){ref-type="table-fn"}    22.1 mo         PDT                                   VA improvement in 63.2% of cases
  2003                      Chatterjee and Gibson[@b13-opth-4-871]   1                                              15 mo           PDT                                   VA improvement
  2005                      Levy et al[@b4-opth-4-871]               1                                              3 mo            Oral steroids                         VA improvement from 6/60 to 6/9[d](#tfn7-opth-4-871){ref-type="table-fn"}
  2005                      Postelmans et al[@b14-opth-4-871]        16[c](#tfn6-opth-4-871){ref-type="table-fn"}   21 mo           PDT                                   VA improvement in 13
  2006                      Lim et al[@b15-opth-4-871]               2                                              12/24 mo        PDT                                   VA improvement in 1, unchanged in 1
  2007                      Coco et al[@b16-opth-4-871]              8                                              22.7 mo         PDT                                   VA improvement in 5, deterioration in 3
  2008                      Fong et al[@b21-opth-4-871]              5                                              12 mo           PDT plus oral steroids                VA improvement in all eyes
  2008                      Chan et al[@b22-opth-4-871]              4                                              12 mo           PDT plus intravitreal triamcinolone   VA improvement in 3, deterioration in 1
  2008                      Vossmerbaeumer et al[@b17-opth-4-871]    1                                              Mid-term        Anti-VEGF (bevacizumab)               VA improvement
  2010                      Leung et al[@b18-opth-4-871]             1                                              8 mo            Anti-VEGF (ranibizumab)               VA improvement

**Notes:**

One case either PIC or multifocal choroiditis.

Mixed results of PIC, POHS, MCP, and other inflammatory conditions.

Mixed cohort of PIC and POHS cases.

Juxtafoveal lesion.

**Abbreviations:** VA, visual acuity; PDT, photodynamic therapy; PIC, punctate inner choroidopathy; POHS, presumed ocular histoplasmosis-like syndrome; MCP, multifocal choroiditis, and panuveitis.
